Invention Grant
- Patent Title: Polypeptides antagonizing Wnt signaling in tumor cells
-
Application No.: US15992345Application Date: 2018-05-30
-
Publication No.: US11033636B2Publication Date: 2021-06-15
- Inventor: Vittoria Zinzalla , Klaus-Peter Kuenkele , Marie-Ange Buyse , Karen Cromie , Stephanie Staelens , Beatrijs Strubbe
- Applicant: Boehringer Ingelheim International GmbH
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Wendy M. Gombert
- Priority: EP17173782 20170531
- Main IPC: A61K47/68
- IPC: A61K47/68 ; C07K16/28 ; A61P35/00 ; C07K16/46 ; A61K39/00 ; C07K16/18 ; C07D519/04
Abstract:
The invention provides novel LRP5-binding polypeptides, and more specifically novel LRP5-binding immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.
Public/Granted literature
- US20180344868A1 POLYPEPTIDES ANTAGONIZING WNT SIGNALING IN TUMOR CELLS Public/Granted day:2018-12-06
Information query
IPC分类:
